Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Cash (2020 - 2025)

Historic Change in Cash for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to $40.4 million.

  • Silence Therapeutics' Change in Cash rose 17310.8% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 10864.76%. This contributed to the annual value of $52.5 million for FY2024, which is 286670.44% up from last year.
  • Silence Therapeutics' Change in Cash amounted to $40.4 million in Q3 2025, which was up 17310.8% from -$23.3 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Change in Cash ranged from a high of $74.0 million in Q1 2024 and a low of -$56.7 million during Q1 2025
  • Its 5-year average for Change in Cash is $2.9 million, with a median of -$1.9 million in 2023.
  • Examining YoY changes over the last 5 years, Silence Therapeutics' Change in Cash showed a top increase of 1670649.72% in 2022 and a maximum decrease of 125310.96% in 2022.
  • Silence Therapeutics' Change in Cash (Quarter) stood at $3.0 million in 2021, then crashed by 1253.11% to -$34.9 million in 2022, then soared by 94.44% to -$1.9 million in 2023, then skyrocketed by 2085.72% to $38.5 million in 2024, then increased by 4.8% to $40.4 million in 2025.
  • Its Change in Cash stands at $40.4 million for Q3 2025, versus -$23.3 million for Q2 2025 and -$56.7 million for Q1 2025.